Hepatitis C and human immunodeficiency virus infection

Hepatology

Volumn 36, Issue 5 I, 2002, Pages

  Thomas, David L ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN;

ANEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HEMOLYSIS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER DISEASE; LIVER TOXICITY; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

DISEASE TRANSMISSION; EPIDEMIOLOGY; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 0036828832     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36380     Document Type: Conference Paper

References (92)

1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
3. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
4. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33:240-247.
5. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines on the management of occupational exposures to HBV, HCV, and HIV and recommendations for post-exposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001;50:1-67.
6. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997;35:3274-3277.
7. Bove JR. Transfusion-associated hepatitis and AIDS. What is the risk? N Engl J Med 1987;317:242-245.
8. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431.
9. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-1690.
10. Kingsley LA, Detels R, Kaslow R, Polk BF, Rinaldo CRJr, Chmiel J, Detre K, et al. Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet 1987;1:345-349.
11. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C, Garcia P, et al. Obstetrical factors and the transmission of human immunodeficiency virus type I from mother to child. N Engl J Med 1996;334:1617-1623.
12. Zanetti AR, Tanzi E, Paccagnini S, Principi N, Pizzocolo G, Caccamo ML, D'Amico E, et al. Mother-to-infant transmission of hepatitis C virus. Lancet 1995;345:289-291.
13. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, Hollinger FB, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. J Infect Dis 1998;177:1480-1488.
14. Thomas DL, Zenilman JM, Alter HJ, Shih JW, Galai N, Carella AV, Quinn TC. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: An analysis of 309 sex partnerships. J Infect Dis 1995;171:768-775.
15. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991;115:764-768.
16. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-1153.
17. Buchbinder SP, Katz MH, Hessol NA, Liu J, O'Malley PM, Alter MJ. Hepatitis C virus infection in sexually active homosexual men. J Infect 1994;29:263-269.
18. Donahue JG, Nelson KE, Munoz A, Vlahov D, Rennie LL, Taylor EL, Saah AJ, et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1991;134:1206-1211.
19. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, Butler K. Mother-to-child transmission of hepatitis C virus: Evidence for preventable peripartum transmission. Lancet 2000;356:904-907.
20. Resti M, Azzari C, Galli L, Zuin G, Giacchino R, Bortolotti F, Marcellini M, et al. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: Results from a multicenter study of 1372 mother-infant pairs. J Infect Dis 2002;185:567-572.
21. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, Cheung L, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-695.
22. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Blood 1994;84:1020-1023.
23. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-1483.
24. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914.
25. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
26. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000;284:450-456.
27. Thomas DL, Astemborski J, Vlahov D, Strathdee SA, Ray SC, Nelson KE, Galai N, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000;181:844-851.
28. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquit Immune Defic Syndr Hum Retrovirol 1993;6:602-610.
29. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999;179:1254-1258.
30. Pol S, Lamorthe B, Thi NT, Thiers V, Carnot F, Zylberberg H, Berthelot P, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28:945-950.
31. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis c virus infection: A meta-analysis. Clin Infect Dis 2001;33:562-569.
32. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis c virus infection. J Infect Dis 2001;183:1112-1115.
33. Soto B, Sánchez-Quijano A, Rodrigo L, Del Olmo JA, García-Bengoechea M, Hernández-Quero J, Rey C, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
34. Benhamou Y, Bochet M, Di MV, Charlotte F, Azria F, Coutellier A, Vidaud M, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-1058.
35. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996;94:746-752.
36. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee CA. The progression of HCV-associated liver disease in a cohort of hemophiliac patients. Br J Haematol 1994;87:555-561.
37. Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996;91:2563-2568.
38. Benhamou Y, Di MV, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001;34:283-287.
39. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001;32:1207-1214.
40. Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C, Vlahov D, et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002;35:1247-1255.
41. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
42. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, Grappin M, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998;12:381-388.
43. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000;356:1800-1805.
44. Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. U.S. Public Health Services/Infectious Diseases Society of America. MMWR Morbid Mortal Wkly Rep 1999;48:1-82.
45. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902.
46. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and HIV progression. JAMA. 2002;288:199-206.
47. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morbid Mortal Wkly Rep 1998;47:1-39.
48. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131-1136.
49. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr Hum Retrovirol 2001;26:340-344.
50. Chamot E, Hirschel B, Wintsch J, Robert CF, Gabriel V, Deglon JJ, Yerly S, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990;4:1275-1277.
51. John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease? AIDS 1998;12:2289-2293.
52. Marcellin P, Martinot-Peignoux M, Elias A, Branger M, Courtois F, Level R, Erlinger S, et al. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 1994;170:433-435.
53. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991;254:423-427.
54. Chun TW, Carruth L, Finzi D, Shen XF, DiGiuseppe JA, Taylor H, Hermankova M, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection. Nature 1997;387:183-188.
55. Laskus T, Radkowski M, Piasek A, Nowicki M, Horban A, Cianciara J, Rakela J. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: Evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000;181:442-448.
56. Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud MA, Trépo C, Inchauspé G. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: Influence of viral load, viral genotype, and cell phenotype. Blood 1998;91:3841-3849.
57. Shimizu YK, Feinstone SM, Kohara M, Purcell RH, Yoshikura H. Hepatitis C virus: Detection of intracellular virus particles by electron microscopy. Hepatology 1996;23:205-209.
58. Sherman KE, O'Brien J, Gutierrez G, Harrison S, Urdea M, Neuwald P, Wilber J. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993;31:2679-2682.
59. Mao Q, Ray SC, Laeyendecker O, Ticehurst JR, Strathdee SA, Vlahov D, Thomas DL. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol 2001;75:3259-3267.
60. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611.
61. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
62. Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, McGowan K, Rosenberg ES, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: Intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002;76:2817-2826.
63. Poles MA, Dieterich DT, Schwarz ED, Weinshel EH, Lew EA, Lew R, Scholes JV. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:170-177.
64. Centers for Disease Control and Prevention. The hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR Morbid Mortal Wkly Rep 1991;40:1-19.
65. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Gunther S, Hess G, et al. Serological pattern "anti-HBc alone": Report on a workshop. J Med Virol 2000;62:450-455.
66. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998;17:6-13.
67. Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, Di Bisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis 1998;26:895-897.
68. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs. Hepatology 1988;8:766-770.
69. Boyer N, Marcellin P, Degott C, Degos F, Saimot AG, Erlinger S, Benhamou JP. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992;165:723-726.
70. Soriano V, García-Samaniego J, Bravo R, González J, Castro A, Castilla J, Martínez-Odriozola P, et al. Interferon α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:585-591.
71. Soriano V, Bravo R, García-Samaniego J, Castilla J, González J, Castro A, Llibre JM. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. AIDS 1997;11:400-401.
72. Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report. Gut 2000;47:694-697.
73. Nasti G, di Gennaro G, Tavio M, Cadorin L, Tedeschi RM, Talamini R, Carbone A, et al. Chronic hepatitis C in HIV infection: Feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. AIDS 2001;15:1783-1787.
74. Landau A, Batisse D, Piketty C, Duong Van Huyen JP, Bloch F, Belec L, Bruneval P, et al. Long-term efficacy of combination therapy with interferon-alpha2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001;15:2149-2155.
75. Sauleda S, Juarez A, Esteban JI, Altisent C, Ruiz I, Puig L, Esteban R, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001;34:1035-1040.
76. Kostman JR, Rodriguez-Torres M, Prokupek D, Brau N, Bonacini M, Hassanein T, Smith J, et al. Results of a multicenter, randomized, double-blind, controlled trial of interferon alfa-2b/ribavirin combination therapy in HCV/HIV coinfected persons [Abstract]. Program and Abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8-11, 2001.
77. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965.
78. Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. International Interferon-alpha. Lancet 1998;351:1535-1539.
79. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
80. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
81. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, Walker R, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990;112:805-811.
82. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
83. Moore RD. Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 1999;29:44-49.
84. Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, Crumpacker C, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-1379.
85. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997;41:1231-1236.
86. Balzarini J, Lee CK, Herdewijn P, De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991;266:21509-21514.
87. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-281.
88. Landau A, Batisse D, Piketty C, Jian R, Kazatchkine MD. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000;14:1857-1858.
89. Gow PJ, Pillay D, Mutimer D. Solid organ transplantation in patients with HIV infection. Transplantation 2001;72:177-181.
90. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE. Correlates of hepatitis C virus infections among injection drug users in Baltimore. Medicine 1995;74:212-220.
91. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000;38:575-577.
92. Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Bréchot C, Nalpas B. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients. J Hepatol 1998;29:12-19.